ZNTL

Business Context and Reporting Period

Zentalis Pharmaceuticals, Inc. (ZNTL) is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), a WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). This Form 10-Q covers the quarterly period ended March 31, 2025. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Total Liquidity includes cash, cash equivalents, and marketable securities. The company reported no debt as of March 31, 2025.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero from $40.6 million in Q1 2024. The prior year revenue was driven by the Immunome License Agreement, which was recognized in a single quarter in 2024. No comparable licensing revenue was recognized in Q1 2025.
• Net Loss vs. Income: The company swung from a net income of $10.1 million in Q1 2024 to a net loss of $48.3 million in Q1 2025. This shift was primarily due to the absence of the one-time license revenue and a significant decrease in investment income.
• Restructuring Charges: The company incurred $7.8 million in restructuring expenses in Q1 2025, compared to none in the prior year. This followed a workforce reduction of approximately 40% announced in January 2025 to extend the cash runway.
• Investment Income Volatility: Investment and other income turned negative at $(2.7) million in Q1 2025, compared to $34.9 million in Q1 2024. This decrease was driven by a $38.3 million decline in the fair value of Immunome stock held by Zentalis.
• Expense Reduction: Despite restructuring costs, total operating expenses decreased by $19.7 million year-over-year, primarily due to lower R&D and G&A costs resulting from the workforce reduction and decreased clinical activity.

Guidance, Outlook, and Risks

• Cash Runway: Management believes existing cash, cash equivalents, and marketable securities ($332.5 million) are sufficient to fund operations into late 2027.
• Clinical Outlook:
  • DENALI Part 2: The first patient was dosed in April 2025. Topline data is anticipated by year-end 2026. Success could support an accelerated FDA approval.
  • Phase 3 Study: Plans to conduct a randomized Phase 3 confirmatory study concurrently with DENALI Part 2b.
  • Other Programs: Data from the TETON trial (uterine serous carcinoma) is expected in the first half of 2026.
• Key Risks:
  • Capital Needs: The company will require substantial additional capital to complete development and commercialization. Failure to raise capital could force delays or program eliminations.
  • Companion Diagnostic: Commercialization of azenosertib depends on the regulatory approval of a companion diagnostic to identify Cyclin E1+ patients.
  • Single Product Dependence: The business is entirely dependent on the success of azenosertib.
  • Manufacturing: Reliance on third-party manufacturers, including those in China, exposes the company to supply chain disruptions and geopolitical risks.

Investor Verification Checklist

• Verify the timeline and enrollment progress of the DENALI Part 2 clinical trial, as this is the primary catalyst for potential accelerated approval.
• Confirm the status and regulatory pathway for the companion diagnostic required for patient selection in the lead indication.
• Monitor the fair value of Immunome stock holdings, as fluctuations significantly impact reported net income/loss and investment income.
• Assess the impact of the 40% workforce reduction on the company's ability to execute late-stage clinical trials and prepare for commercialization.
• Review the manufacturing supply chain for azenosertib, specifically regarding reliance on third-party manufacturers in China and potential trade or geopolitical risks.
• Track the company's cash burn rate relative to the stated runway into late 2027 to anticipate potential future financing needs.